Why is QMS Medical Allied Services Ltd falling/rising?

4 hours ago

Share Via

As of 27-Jan, QMS Medical Allied Services Ltd has seen its share price fall by 4.93% to ₹82.00, continuing a trend of underperformance relative to key market benchmarks and raising questions about the stock’s near-term prospects despite some positive operational metrics.

Recent Price Movement and Market Comparison

On the trading day ending 27 January, QMS Medical’s shares underperformed not only the broader Sensex but also its sector, slipping by 4.93% compared to the Sensex’s marginal decline of 0.23%. This underperformance is consistent with the stock’s trend over longer periods. Over the past month, the stock has declined by 10.24%, significantly worse than the Sensex’s 3.33% fall. Year-to-date, the stock is down 8.48%, more than double the benchmark’s 3.65% decrease. Over the last year, the stock has posted a steep 20.85% loss, while the Sensex has gained 10.28%. The three-year performance is even more stark, with QMS Medical plunging 53.29% against a 43.01% rise in the Sensex.

Technical Indicators and Trading Activity

Technical analysis reveals that QMS Medical is trading below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning typically signals bearish momentum and investor caution. Despite this, there has been a surge in investor participation, with delivery volumes on 23 January rising by over 790% compared to the five-day average. This spike in trading volume suggests heightened interest, although it has not translated into price gains. Liquidity remains adequate for trading, supporting the stock’s accessibility to investors.

Fundamental Strengths Amidst Price Weakness

Despite the share price decline, QMS Medical exhibits some attractive fundamental metrics. The company’s return on capital employed (ROCE) stands at a healthy 13.6%, indicating efficient use of capital. Its enterprise value to capital employed ratio of 1.4 suggests the stock is trading at a discount relative to its peers’ historical valuations. Furthermore, the company’s profits have grown by 19.6% over the past year, even as the stock price has fallen. The price-to-earnings-to-growth (PEG) ratio of 1.4 reflects a valuation that is not excessively stretched given earnings growth prospects.

Institutional Interest and Its Implications

Institutional investors have increased their stake in QMS Medical by 1.6% over the previous quarter, now collectively holding 1.61% of the company. This growing institutional participation may indicate confidence in the company’s fundamentals, as these investors typically possess greater resources and analytical capabilities than retail investors. However, this has yet to reverse the stock’s downward trajectory.

Challenges Weighing on the Stock

QMS Medical’s recent financial results have been underwhelming, contributing to investor caution. The company reported flat results in September 2025, with interest expenses for the nine-month period rising sharply by 93.17% to ₹6.22 crores. Additionally, the quarterly earnings per share (EPS) hit a low of ₹1.61, signalling pressure on profitability. These factors have compounded concerns about the company’s near-term earnings momentum.

Moreover, the stock has consistently underperformed the broader market and its benchmark, BSE500, over the last three years. This persistent lag, combined with negative returns over multiple annual periods, has eroded investor confidence and contributed to the sustained downward pressure on the share price.

Outlook for Investors

While QMS Medical Allied Services Ltd offers some fundamental appeal through its valuation and profit growth, the stock’s prolonged underperformance and recent weak results have weighed heavily on its market performance. Investors should weigh the company’s attractive ROCE and institutional interest against the challenges of rising interest costs, subdued earnings, and technical weakness. The stock’s discount to peers may present a value opportunity for long-term investors willing to tolerate near-term volatility, but caution remains warranted given the consistent underperformance relative to benchmarks.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE